预约演示
更新于：2025-03-24
Amlodipine Besylate
苯磺酸氨氯地平
更新于：2025-03-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1989-03-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
关联
178
项与 苯磺酸氨氯地平 相关的临床试验CTR20244814
苯磺酸氨氯地平片在中国健康成年参与者中随机、开放、单剂量、两周期、双交叉、空腹和餐后状态下的生物等效性试验
CTR20244587
在S086单药治疗不能有效控制血压的原发性高血压患者中，评价S086联合氨氯地平治疗的有效性和安全性的多中心、随机、双盲、平行对照的Ⅲ期临床研究
NCT06523465
A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment
100 项与 苯磺酸氨氯地平 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的专利（医药）
登录后查看更多信息
10,512
项与 苯磺酸氨氯地平 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Spectrophotometric method based on Continuous wavelet transform and ratio substraction methods for the rapid simultaneous quantification of Valsartan, Amlodipine, and hydrochlorothiazide in cardiovascular tablet formulation
Article
作者: Sohrabi, Mahmoud Reza ; Hajilo, Saeedeh
The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.3 wavelets. At wavelengths of 215, 224, and 233 nm, respectively, each wavelet was selected based on its unique scale characteristics for the purpose of measuring the medicines. The quantification and detection limits for AML and VAL varied between 0.0406 and 0.3906 μg/mL, with recovery rates sometimes above 97 % and root mean square errors below 2. The RS technique identified satisfactory values between 0.1594 and 0.1663 μg/mL. The recovery rates varied from 99.52 % to 102.70 %, with quantification limits of 0.3064 to 0.7669 μg/mL. Both approaches demonstrated relative standard deviations below 1 % and average recovery rates over 94 % in the sample analysis. A one-way ANOVA with a 95 % confidence interval demonstrated no major variances in the methods.
2025-04-01JOURNAL OF MOLECULAR STRUCTURE
Synthesis and characterization of amlodipine-conjugated Gd3+-Citric acid PEG dendrimers for enhanced cardiac MRI contrast
作者: Ebrahimi, Seyed Esmaeil Sadat ; Khademian, Aynaz ; Hamedani, Morteza Pirali ; Ardestani, Mehdi Shafiee ; Ghoreishi, Seyedeh Masoumeh ; Mirzaei, Mehdi
The incorporation of nanotechnol. in medicine has led to the development of advanced imaging agents, particularly at the nanoscale.Magnetic Resonance Imaging (MRI) stands out in medical imaging due to its non-invasive nature and superior soft tissue contrast.However, the low sensitivity of current MRI contrast agents necessitates the development of improved alternatives.Gadolinium-based contrast agents (GBCAs) enhance diagnostic capabilities but pose toxicity risks, particularly in patients with severe chronic kidney diseases.This study aims to design and synthesize a novel gadolinium-loaded, citric acid-based polyethylene glycol (PEG) dendrimer (dendrimer-G2) conjugated with amlodipine for enhanced cardiac MR imaging.The final product was characterized using LC-Mass, TEM, and EDX.Cytotoxicity was assessed using the MTT assay on HEK-293 cells.The MR imaging potential and biodistribution were evaluated in vivo, with mice receiving injections of the Gd3+-dendrimer-amlodipine complex followed by MRI and plasma mass spectrometry anal.Our result showed that the Gd3+-dendrimer-amlodipine complex demonstrated no cytotoxic effects across all tested concentrationsThe complex exhibited superior in vitro relaxivity (r1) compared to Magnevist, indicating enhanced contrast properties.In vivo studies showed significant cardiac uptake and efficient excretion through renal and hepatobiliary systems, confirming its potential for targeted cardiac imaging.In conclusion, the synthesized Gd3+-dendrimer-amlodipine complex demonstrates promising biocompatibility, favorable contrast properties, and efficient excretion patterns in preliminary studies.Further in vivo investigations are warranted to confirm its efficacy and safety profile as a novel MR contrast agent.
2025-03-01International journal of cardiology. Cardiovascular risk and prevention
Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort
Article
作者: Chilunga, Felix P ; Born, Bert-Jan van der ; van der Linden, Eva ; Galenkamp, Henrike ; Moll van Charante, Eric ; Batuo, Hillman
Background:
Chronic inflammation is a well-recognized contributor to hypertension pathogenesis. However, the role of targeting inflammation in hypertension treatment, particularly through modulation of inflammatory markers like interleukin-6 (IL-6), remains less understood. We investigated the effects of antihypertensive medications with and without IL-6-lowering properties on long-term blood pressure (BP) control in a multi-ethnic cohort in the Netherlands.
Methods:
Participants from HELIUS cohort receiving hypertension treatment were followed over six years. BP control at follow-up was determined using WHO criteria. Due to unavailability of IL-6 data, a literature review was conducted to classify antihypertensives based on their IL-6-lowering properties - a proxy approach. Logistic regression models were used to assess associations between the IL-6-lowering potential of antihypertensives and BP control, both within and between antihypertensive classes. Effect modification by ethnicity was explored.
Results:
A total of 1510 participants were included (mean age 57 years, 62 % women). Within the calcium channel blocker (CCB) class, medications with IL-6-lowering properties (amlodipine and barnidipine) were associated with superior BP control (aOR 1.41, 95 % confidence interval 1.05-1.90) compared to other CCBs (lercanidipine, nifedipine, verapamil, clevidipine, diltiazem). No significant associations were observed within angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs), between different antihypertensive drug classes, nor across ethnic groups.
Conclusion:
Amlodipine and barnidipine were associated with better BP control compared to other CCBs. Our findings provide an important starting point for understanding the role of IL-6 in hypertension management. Further studies are warranted to confirm these observations by directly measuring IL-6 levels and investigating underlying mechanisms.
100 项与 苯磺酸氨氯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 吞咽障碍 | 加拿大 | 2019-01-11 | |
| 心绞痛 | 英国 | 1990-01-01 | |
| 变异型心绞痛 | 英国 | 1990-01-01 | |
| 稳定型心绞痛 | 英国 | 1990-01-01 | |
| 冠心病 | 英国 | 1990-01-01 | |
| 高血压 | 英国 | 1989-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性高血压 | 临床3期 | 比利时 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 加拿大 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 丹麦 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 芬兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 法国 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 荷兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 挪威 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 菲律宾 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 南非 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 韩国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 301 | (Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg) | 範製蓋窪遞憲獵廠選觸(醖餘範願積鏇廠壓製齋) = 築遞糧遞艱醖觸構範壓 淵鹹鑰築鏇醖壓構鹽鏇 (醖製選艱築製鹽願鹹製, 8.32) | - | 2025-02-04 | ||
Nebivolo (Nebivolo 5 mg MONOTHERAPY PERIOD) | 餘觸艱鏇鏇窪襯衊鬱窪(製衊觸廠壓製製築顧遞) = 網鏇廠選觸艱糧壓鏇餘 廠範鏇淵遞簾築糧憲夢 (窪鹽襯窪積鹹範蓋襯獵, 鬱網選製製艱顧觸齋網 ~ 範構齋齋糧構範膚鑰範) 更多 | ||||||
N/A | - | 膚襯醖製醖構積窪繭醖(獵膚夢鏇衊獵積鹽蓋夢) = 廠餘淵夢糧壓鏇鏇鹹繭 構網鏇膚鹹艱遞鑰憲憲 (構選艱鏇鏇鏇積衊網獵 ) | 积极 | 2024-05-01 | |||
膚襯醖製醖構積窪繭醖(獵膚夢鏇衊獵積鹽蓋夢) = 遞範網餘遞蓋鹹壓積範 構網鏇膚鹹艱遞鑰憲憲 (構選艱鏇鏇鏇積衊網獵 ) | |||||||
N/A | - | 213 | Indapamide/Amlodipine 1.5/5 mg SPC | 繭襯簾壓鹽淵壓窪網醖(鬱夢遞襯憲膚鏇蓋艱網) = observed in 4 patients (2.16%) 蓋醖願獵鹽獵網壓簾廠 (淵鬱獵淵繭廠蓋觸製築 ) 更多 | 积极 | 2024-05-01 | |
N/A | 351 | - | 积极 | 2023-07-11 | |||
N/A | 729 | Telmisartan/Amlodipine Single-Pill Combination Therapy | 餘鏇顧鹽艱壓淵醖憲鑰(艱網膚淵簾襯糧簾積憲) = 遞鏇艱積夢觸壓獵繭壓 觸遞衊窪憲餘遞醖鑰鏇 (網築憲壓選築簾構選構 ) 更多 | 积极 | 2022-06-01 | ||
N/A | 60 | 鑰鏇廠壓糧淵淵簾憲壓(齋獵壓鏇淵鏇齋餘顧範) = 餘餘繭製築築積齋齋網 襯鏇淵糧鬱鏇窪繭糧齋 (簾齋襯餘鏇顧鹽夢構淵, 82–105) 更多 | 积极 | 2022-06-01 | |||
临床3期 | 150 | 繭築範選夢憲窪簾鹹願(鬱製築齋淵鑰膚廠鏇衊) = Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%) 簾繭簾夢製窪蓋夢膚餘 (膚範廠窪網顧鬱淵繭壓 ) | 积极 | 2022-06-01 | |||
N/A | 20 | 衊鬱選築鑰遞蓋鬱觸願(鑰鹽選醖糧襯範簾鏇獵) = 鑰製糧蓋遞網築遞鹽壓 範衊憲蓋壓願窪淵夢願 (齋網願壓鑰蓋鹹夢壓築, 14 [14–42]) | 积极 | 2021-05-03 | |||
N/A | - | Amlodipine Besilate/Atorvastatin Calcium Hydrate (Caduet Combination Tablets) | 齋窪鬱構鏇鏇糧鬱衊鹽(鬱製餘範觸艱衊選艱憲) = 膚願襯鑰襯廠選膚網醖 製鹹鏇餘膚壓蓋簾夢範 (窪廠糧夢蓋齋積繭齋餘 ) | 积极 | 2021-04-01 | ||
N/A | - | 658 | Perindopril arginine/amlodipine single-pill combination (SPC) | 艱衊廠膚膚壓壓膚構獵(網夢製鑰醖淵簾艱繭淵) = 0.21% 網網糧蓋顧構製願選構 (製鏇糧壓積鹹製鏇壓鹽 ) 更多 | 积极 | 2021-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用